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Options for Breast Cancer Prevention in High-Risk Patients
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Abstract
Breas· ca ~r IS the most lreque111y diagnosed non-skin caocer rn
women. arxl one in e ghl Yromen will develop breasl caocerwi!hin Ifie r
b.fellmes. Unfortunate y, the strongesl nsk factors for breast cancer (i.e.
age, family history, hormonal lac1ors) are no1 eastly rnodlheo. There
is some evdence 1hat chemofl"evan11ve drugs may be able to prevent
breast cancer 1n h1gh-nsk patients. Tamox1fen and raloxifene have been
shown to reduce Iha nsk of breast cancer 1n h1gh-nsk women but may be
associated with several senous adverse evenls Clinical tnals are current
ly 1n p<ogress 10 de1enn1ne 11 aromalase mh1b1tors are a viable allematrve
for b<east cancer p<evenuon, as they may be considered effecuve in 1he
early treatmenl of breast cancer For J:lllients with BRCAt and BRC/.2
mu1a1ions. a bilateral prophylachc mas1ectomy may be an option. This
artcle discusses the nsks and beneflls of available trea1ment opt10ris for
breas1 cancer J:IOV91'lll0tl in hlgh·llSk patients.
Introduction
Breast cancer s Ille most frequen:ly diagnosed non-skin cancer tn
women arxl me second most com110n cause of cancer death ui women.1
One n eighl women wil l develOp tt1eas1 cancer w;lhm their !lfellmeS 2
Some breast cancers are esuogen-Oependent for growtil and are l<OOwn
as esuogen recepror pos ttve (ER·JX>Slllve) breast cancers. oiher oceasr
cancers are considered estrogen recepror negattve (ER-negalJVe 1 and
comixise<l or cers witnout esuogen receptors 1 The presence or these
receptors IS an llTIJX>rtant part of 1een1Jfymg useful treatmenr opoons •
Unfortunately. the s1ronges1 nsk fac1ors for breast cancer (1.e age ramlly h1Story, hormonal factors) are not easily modified In high-nsk patienis,
muraoons 1n BRCA 1BRCA2 greatly increase lifetime nsk of cancer.5
Prophylactc masl9Cromies for BRCA t and BRCA2 mutatt0n earners are a
growing trend m breast cancer prevention However, since not all women
with these muta1t0ns will develop breast cancer, those consldenng thlS
alternaove should receive counselmg on ell available options before making
a final decis10n •Thus, other preventive strategies must be considered.
There IS some evidence lhal chemoprevenbve drugs may be able to
prevem breas1 cancer Currently, chemopravention may be considered tor
patJents a1 a high nsk for developmg breast cancer based UJX>n family h1Story, as the benefns do no1 outweg1 the nsks for routine use in all patients.'
Tamoxifen
Tamoxifen a seleeove estrogen receixor modulator (SERM was air
proved by the Food and Drug Adm n1Straoon (FDA) mthe late 1990s for
breast cancer chemop-evenoon By compebovely 0tnd1ng estrogen recepiors 1n breast llSSue. deereasing DtJA syntheslS end inh1tl1lllJ es:mgen
e~eciS, ramoxJen IS shown to redu:e the nsk of breast cancer t1f oo-50
pertem lt'I hgh-nsk VtOmen 11 In contrast estrogen recep!Drs Ill the u:erus
are sllmulated rather tnen lt'lh a:ed by ramox1fen. Estrogenc erects 11 1t1e
uterus 1ncr13ase the nsk of endome1181 cancer Paoenis taking tamoxlfen
am also at mcreased nsl< of lhromboemlxlhc events. These nsks require
1amox1mn ID carry blaelc box warnings for ut13nne mahgnancies. s1ro!ce
and pulmonary emlxll1Sm which hn11 the use of thlS drug for propf1ylact£
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meas.ires.:.io Oesp;:e l1l9 possible side effects, the use o' iamOxlfer> as a
pmphylactx: measure IS supported by two lo~rm slUdJeS. wtoch ronctuded these side effecis do not persist, while tile benefits do.9•11
The Royal Marsden Tnal included 2.47 1women bet'Ween 30 and 70
years of age with a family h1Story of breast cancer who were randomrzed
to rake either tamoxtfen or placelxl for eight years. Results did not show
an overall reducoon in breast cancer evenlS be:ween the tamoxifen and
placelxl groups (p..0.2). However, following the eight-year acllve phase, the
women participated In six-month follow-ups, and a blinded follow-up srudy
was performed 20 years later {median follow-up 13 years) to d910rmine
whether tamox1ten provided 1ong-te1m benefits to overall breast cancer and,
spectooally. with ER-positive breast cancers. Overall, 209 b<east cancer
cases, 1nclud1ng 186 invasive cases, were documented with no differences
noted between tamox1len and placelxl groups (p..O 2). Of the 111Vasive breast
cancer cases. the estrogen receptor status was ava1labl9 for 180. Of these,
139 were ER-JX>smve, with 53 occumng in the ~moxlfen group and 86 occurrmg :n the placelxl group. ResutlS showed that the iamox!fen group had a
39 percent lower incidence of mvaslV9 ER-posr.ive breast carx:ers versus the
placelxl group (p,.().005). The adverse even: pm"'es tor lxllh arms occurred
pmdominantJy dunng the O'llatment perod, wo:hgynecolog£ :Oxi:iiy OOIOQ
!he most chmcally 1mJX>rtant There was no evcence o' any increase in the
ll'IOOenoe of non-breast arxl non-endomeinal cancers. rus study suggesrs
ramoxr.en provides long-term nsk reducoon forER-posltlVe treastcaooer•
The n:emaoonal Bteast Cancer lnrervenoon Stooy 1Bl8-i was a 'ive-year
double b"nd randomlZed ll181companng1amox~n to placebo in women Wllll
an ocreased nsk for breast cancer.11 Tt19 results of ttus study whd1 rcluded a
total or 7 154 women, found a statJSIJCa!ly sgmfK:ant decrease r1 the incidence
or ER·P>s111va breast cancer 1n the ramoxtfen grcup (p,.Q.O 13) Regarding side
effects, a sgmf1cant increase 1n endometnal cancer was found in the 1amoxrren
group dunng the active period (P=0.02), but lollow1ng the acove peood, the d1f·
ference was not s1gn1f1cent (p..0.2). The tamox1fen group also had a significant
111Crease in thromlxlemlxlltc events (p..0.001) as well as deathS (p:0.028),
but no spec1f1c cause of death was s1gmficant The 96-month follow-up of this
study also demonstrated the err1cacy of tamox1len for the prevention of breast
cancer, reP>itmg the development of 337 total bteastcancercases with a 27
percent lower incidence rate with tamox1fen than placelxl (p:0.004). Overall,
a 32 percent reduct10n m breast cancer was seen 1n years zero to four, and 44
percent thereafter no reduct10n was seen 1n ER-oegallve breast cancer. The
nsk reducoon was found to be greater for premeoopausal women, who also
had a lower number of endometnal cancer cases and ihromlxlemlxl!K: events.
Therefore, these teSullS support the use of ramoitfen as chemopreventnn in
J,Yemenopausal women ThlS follow-up srudy suPJX>ns kl~rm oonefils of tamoxlfen for ER·pos1!JV9 breast cancer nsk reoUC110n wh\9 showing the adverse
e"ects are urekey to perstSt Jl!Sl the treatment phase
Raloxilene
Ra bx Jene IS a seleewe estrogen recepeor modulalDr SERM that compeonvery antagonizes estrogen-induced ONA trallSCJ 1poon of estrogen on
receptors lfl breast and utenne t1Ssues •:It aISO acts as an estrogen agon1St
11 lxlne therefore 1ncraas1ng lxlne density Labeled lndcaoons for ralox·
k'ene include preventt0n and treatment of osteopOrostS mp.:ist-menopausal
women as well as the prevent10n of breast cancer ui tugh-nsk patients. tJ
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The clinical effectJveness of raloxifene is evident in two prominent
trials. The Mulnple Outcomes of Raloxifene Evaluation (MORE) is a
mutucenter, double-blind, randomized 1rial comprised of 7,705 women
who were followed from 1994 to 1998.12 The primary outcome of the
trial was osteoporosJS preventJon, with breast cancer prevention as a
secondary end point Raloxifene reduced the nsk of invasive ER-pos1irve
breast cancer by 00 percent but did not have a stallstically significant
effect on invasive ER-negative breast cancer. The overall risk of invasive
breast cancer was reduced by 76 percent. Ills also important to note
that raloxifene did not increase the risk of endometrial cancer in the
study patients. The Continuing Outcomes Relevant to Evista (CORE)
trial is a continuation of the MORE trial, where patients' raloxifene treatment was continued for four additional years in order to study long-term
effects of therapy. 14 Women who agreed to continue in the study {n=
4,01 1 patients) were either continued on placebo therapy or assigned
to raloxifene tf they received acnve treatment m the previous trial. The
women who received ralox1fene had a 59 percent reduced incidence of
invasive breast cancer compared ro the placebo group. This included
a 76 percent reduction 1n ER-pos11ive 1nvas1ve breast cancer and no
stat1st1cally significant reduction 1n ER-negative 1nvas1ve breast cancer. It
could not be determined whether 1he reduction was a result of 1he 1n11lal
four-year therapy or the continuation of treatment in the CORE trial.
The adverse evenlS from ralox1tene treatment were s1m1lar for both the
MORE and CORE tnals. 12•14 Reported events included hot Hashes, deep
vein thrombosis, retinal vem thrombosis, leg cramps, myocardial infarction, stroke, cataracts, ovarian cancer and breast pain. However. none
of the events were statlS!lcaUy sign'ficant m the treatment group versus
the placebo group. A higher incidence of pulmonary embolism occurred
in the raloxifene group compared to placebo for the eight-year period of
treatment Although the increased risk of thromboembolic disease was not
overall statistically significant in the treatment group versus placebo, the
researchers did note that raloxifene should be used with caution 1n pallents
who are already at an increased nsk ot t11rombOembOl1c events.
The Nanonal Surgical Ad11vant Breast and Bowel Propct {NSABP)
Study ofTamox1fen and Raloxifene (STAR) mal was conducted as a
fo llow-up to the Breast cancer Prevention Tnal (BCPT). which studied the
effecr1veness of tamox1fen for preventing breast cancer. '5 To obtain FDA
approval of ra10x1fene as a preventative tl1erapy for patients at h1gh-rJSk for
breast cancer, researchers compared tamoxifen to raloxifene. The STAR
trial was a prospecllve, double-blind, randomized, phase-Ill tnal conducted
from July 1, 1999, to Dec. 31, 2005. Within that time penod, therapy was
given tor five years with a one-year follow-up. Eligible participants included
women who were required to have a five-year predicted breast cancer risk
of at least 1.66 percent based on the Gail Model, postmenopausal, and
not currently receiving tamoxifen or raloxifene therapy. At baseline, 19,747
women were enrolled into treatment with a mean age of 58.5 years and a
mean five-year predicted breast cancer risk of 4.03 percent. Patients were
randomized to receive tamoxiten or raloxifene and were stratified by age
and race. Outcome comparison between treatment groups was based on
determined rates of incidence per 1,000.
At the conclusJOn of the STAR trial, there was no statistically significant
d1fference between i:amoxiten (4.3 oer 1,000) and raloxifene (4.41 per
1,000) 1n preventing invasive breast cancer.15 The result was not staustr
cally stgnificant, although a difference was noted in prevention of non-mvas1ve breast cancer, spec1fically. fewer patients 1n the tamox1ten group {1.51
per 1,000) developed non-invasive breast cancer than the raloxifene group
(2.1 1 per 1,000). There are multiple secondary endpoints to be considered
in the STAR tnal Within the raloxrfene group. there was a trend towards a
decreased 1ncKlence of uterine cancer, although the result was not statlSllcally significant Raloxifene did show a statistically significant reduction m

uterine hyperplasia and hysterectomy events When compared to tamox1fen. Overall, raloxifene has a decreased effecron adverse events associated with utenne tissue, Raloxifene patients had significantly fewer cases
of deep vein thrombosis and pulmonary embolism. This result is significant
for those patients who have an already Increased risk of thromboembolic
event pnor to SERM treatment.
In conjunction with the STAR tnal, the Patient-Reported Symptoms
and Quality of Life During Treatment With Tamoxifen or Raloxifene for
Breast Cancer Prevention trial captured the effects of SERM treatment
on patients included in the trial. 16 The report concluded no significant
difference between treatment groups tor overall physical and mental
health. Raloxifene patients did experience a significant decrease in
sexual interest (p= 0.009) and expenenced fewer musculoskeletal
problems, such as leg cramps {P=0.002). Tamoxiten patients experienced significantly more vasomotor symptoms (p«l.001). Both treatment groups experienced adverse events related to bladder problems
(p«l.001), gynecological problems (p«l.00 1) and leg cramps (p«l.00 1).
This report 1s a useful tool to evaluate quahty·of-hfe outcomes for two
treatment methods with similar pharmacological outcomes. 16
Ac the conclusJOn of the STAR tnal, the researchers noted some
shortcomings of the study. 16 Although attempts were made to represent
racial and ethnic groups within the populallOn of North America, the tnal
did not meet the goal of proportlonal representation of the populaaon.
ThlS is significant In evalualmg the treatment of patient populations who
may not have been adequately represented within the tnal. The STAR
trial was also unable to evaluate the adequate length ot SERM treatment needed to prevent invasive breast cancer. '5 The Ina.I did provide
necessary data to show that eight years of treatment reduced the
incidence of invasive breast cancer, but decreased adverse effects could
be achieved with a shorter treatment. The researchers noted that lack of
information on treatment duration should not deter treatment, as longterm studies have shown that tamoxiten is safe and effective 25 years
alter tile drug was t1rst approved tor prevenoon. Whether or not one
SERM was preferred over another was not concluded within the STAR
trial, however, ralox1fene was FDA-approved for preventallve treatment
of breast cancer. ' 5•11 Researchers believed that physJCians may be
more likely to convert to raloxifene treatment for breast cancer prevenaon since ralox1fene therapy exhibited decreased adverse events m the
STAR tnal. Currently, neither SERM 1s recommended over another m
prevention of invasive breast cancer guidelines.
Aromatase inhibitors
While tamoxiten and raloxifene are the medications conventionally used for
breast cancer prevention, aromatase inhibitors are an emerging option. 16
Aromatase converts androgens to estrogen in the adrenal glands and other
tissues: however, this is a minor estrogen synthesis pathway in premenopausal women, who synthesize estrogen mainly in the ovaoos. For this
reason, aromatase inhibitors have little effect on estrogen synthesis in premenopausal women. Conversely, aromatase 1s lhe mam estrogen pathway
in JX)Stmenopausal women, so aromatase inhibitors are reserved tor use in
this population.19 Tl1ree aromatase inhibitors are currently available anastrozole, letrozole and exemestane. 13 All three are 1n:ticated for the treatment of
early to advanced ER-pos1hve breast cancer, and all three drugs suppress
almost all estrogen production in postmenopausal women. 11•1'
W1th1n the MORE tnal, it was hypothesized that 1nh1bitJOn of aromatase is
at least equally effective 10 raloxlfene in breast cancer prevenoon, whch 1n111ated the turtl1er research of all three aromatase inhibitors for FDA approval
as preV9ntative treatment of breast cancer 12,20 Currently, letrozole and
exemestane are in phase-Ill trials and include postmenopausal women with
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no p<ior history of breast cancer. Lelrozole and exemestane Dials are set to
te completed w1th1n the next five years. 2'.22 However, anastrozole research
is soll 1n the recrumrg phase with no estimated conclusion date.zi
The role of aromatase inhibttors 11 preventing breast cancer has yet tote
shown. Because aromatase mhiblto-s are known tote successful for early
breast cancer treatment, It IS possible that aromatase inh1b1tors are useful m
preventing breastcancer. lfofficacy is shown, aromataso inhibitors should be
compared to the current standards of prevention, raloxifene and tamoxifen.
Bilateral prophylactic mastectomy
For patients woo want a higher risk reduction than chemoprevention can
provide, a bilateral prophylacoc mastectomy {BPM) may te an option. This
radical, irreversible procedure is mainly reserved for high-nsk women classified by a mutation of the BRCA t and BRCA2 or a genetic predisposition
for breast cancer. Several studies on this topic have determined at least a
90 percent risk reductionP42' Several different types of mastectomies exist,
with each type removing varying amounts of breast llSsue. However, the nsk
cannot be completely eliminated tecause 100 percent of the breast IJssue IS
not removed in the surgeries. Mastectomies removing greater percentages
of breast tissue are lound to be more effecove.11While studies show a significant risk reducoon in mcdence of breast cancer, mastectomies can also have
p:;ychosocial effeclS on the patient regarding appearance, sexuality, body image and emobonal ui:set26 When discussing possible prophylacoc measures
with paoents, It ts important to weigh the nsks versus oonefits as well as to
ensure that the patJentclearly understands all aspects of this procedure.
Conclusion
In the past few decades, chemoprevention with tamoxifen and raloxifene
has been used as the therapy of cf-oice in preventing the development of
breast cancer in hgh-risk patients. The studies have demonstrated similar
efficacy in the prevention of breast cancer with either SERM treatment
but, at the same time, noted different adverse event profiles. Addmonal
therapies, such as aromatase mhibtors, are currently being studied for use
in h1gh-nsk pallents with possible significance mtreatment for the future.
Recently, mastectomies have gamed attention as another optJon for breast
cancer prevent!On although they are reserved for the highest-nsk pabenlS
due to the irreversible nature of this treatment option and its risks. Whether
or not radical treaoment or chemoth9rapeulic options are better for preventing breast cancer in high-nsk patients has yet to be seen 1n a single study
Considering incl1vldual pabents and their risk for breast cancer IS lmJXJrtant
in deciding which type of preventative treatment patients should receive. As
women contJnue to become more proactive in breast cancer prevention, It
is anticipated that an expans10n of preventative therapy will continue.
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